Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Investor Presentation (July 2022)

42 slides from Windtree Therapeutics's investor presentation, Jul 18, 2022

  1. Slide 1: Windtree Therapeutics Company Overview

    Windtree Therapeutics N Company Overview July 18, 2022 SR we WINDTREE (NASDAQ: WINT)

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27Aof the Securities Actof 1933, as amended, and Section21E ofthe Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Company's c

  3. Slide 3: Windtree Therapeutics and Istaroxime Highlights

    Windtree Therapeutics and Istaroxime Highlights v v Biopharmaceutical company with advanced clinical focused on significant acute CV markets with high unmet needs and with supportive regulatory paths and designations (NASDAQ: WINT) Through three Phase 2 global studies, lead asset istaroxime has cons

  4. Slide 4: Pipeline

    Pipeline Lead Produc Indication Phase | Development Status Plana second Phase 2b cinical tial in~300 patients ena caer Tack Istaroxime ‘Acie Heat Faitre Phase 2 largeted o start once cial tal operations arefuly Gora funded Positive Phase 2 study Potential for Istaroxime Eaty Cardiogenic Shock Phase

  5. Slide 5: Strategy for Value Creation

    Strategy for Value Creation 2022 2023 Q2 Q3 a4 Qi Q2 Istaroxime Cardiogenic Shock © (ikem {SeIsMic) Positive Results Istaroxime Heart Failure ‘Acute Heart Failure Study (transition to Phase. ~| Eatly Cardiogenic Shock | Registration Study" y WINDTREE “syintiaton peng poste dn replay inp and sdegute

  6. Slide 6: Istaroxime Early Cardiogenic Shock

    Istaroxime Early Cardiogenic Shock Additional potential indication in active clinical development

  7. Slide 7: Cardiogenic Shock

    Cardiogenic Shock A severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high filling pressures of the heart and decreased urine output. Itis a treatment emergency » Caused by severe impairment of cardiac function that results in diminished c

  8. Slide 8: Early Cardiogenic Shock Treatment

    Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity to Address Significant Unmet Need ~ No Satisfactory pharmacological intervention to reverse the conditions Available therapies have unwanted side effects such as risk for arrhythmias, decreasing blood pressure, renal dysfunction and

  9. Slide 9: Early Cardiogenic Shock Treatment: Accelerated Pathway

    Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Pathway Potential for a relatively fast and less expensive developmental and regulatory pathway Sponsors are potentially not required to show benefit other than an FDA Regulatory increase in blood pressure to support

  10. Slide 10: Istaroxime — Novel First-in-Class Therapy

    Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve ‘systolic contraction and diastolic relaxation of the heart Dual Mechanism of Action ‘Stimulation of SERCA2a activity Inhibition of the sodium- e enhances calcium reuptake ee sen ' fenuling improvement the Betas pu

  11. Slide 11: Rationale for Istaroxime in Cardiogenic Shock

    Rationale for Istaroxime in Cardiogenic Shock Based on Phase 2 Studies in Acute Heart Failure In the positive Phase 2a and Phase 2b studies in Acute Heart Failure, istaroxime demonstrated: ¥ Significantly improved cardiac function ¥ Significantly improved systolic blood pressure ¥ Attractive tolerab

  12. Slide 12: SEISMIC Early Cardiogenic Shock Study

    SEISMIC Early Cardiogenic Shock Study Clinical strategy: Start development with patients in early cardiogenic shock caused by severe heart failure WINDTREE 60 patients in early cardiogenic shock (SBP 75-90mmHg) with AHF Study drug was infused for 24 hours in a 1:1 randomization to placebo or istarox

  13. Slide 13: Difference in SBP Profile

    202102 Difference in SBP Profile mHg) Change from Baseline in SBP (m Systolic Blood Pressure AUC through 6 Hours - mI TT Population Bistaroxime ‘Placebo wo304S ass Hours from Infusion Intitation 3)

  14. Slide 14: Systolic BP Improvements Persisted over Hours

    Systolic BP Improvements Persisted over 24 Hours Systolic Blood Pressure ‘mITT Population 1° ~* Istaroxime © Placebo ‘Change n SBP (mmHg) P=0.025 for AUC Hours from Infusion Iniation a6 WINDTREE 24

  15. Slide 15: Cardiac Function Improvement

    Cardiac Function Improvement Echocardiography demonstrated improvements in key systolic and diastolic cardiac function measures including: » Cardiac index significantly increased » Stroke volume index substantially increased (4 mL/m?) approaching statistical significance » Other echocardiographic me

  16. Slide 16: Treatment was Associated with a Favorable Renal Profile

    Treatment was Associated with a Favorable Renal Profile Renal function was not decreased in istaroxime treated patients Estimated Glomerular Filtration Rate ‘ nT Populaton 5 z. i Eo Ba H i Ba * winornes

  17. Slide 17: Comparison of Doses

    parison of D 1.0 pg/kg/min Produced a Favorable Effect on SBP 1.0 ug/kg/min dosing was associated with: + Early, rapid SBP increase and improvement in more echocardiographic assessments of cardiac function + More favorable adverse event, serious adverse event and clinical event profile 1s | 210 voKo

  18. Slide 18: SEISMIC Results Summary

    SEISMIC Results Summary SEISMIC was a positive study in early cardiogenic shock patients v Systolic blood pressure significantly increased within the first 6 hours of initiating the infusion (p=0.017) and the increase was maintained throughout the 24-hour infusion (p=0.025) SBP increases were rapid

  19. Slide 19: Relevance to the Acute Heart Failure (AHF) Program

    Relevance to the Acute Heart Failure (AHF) Program * The early cardiogenic shock trial results are consistent with Windtree’s Phase 2 AHF studies and complementary to further advancement in AHF. + While SEISMIC was an early cardiogenic shock study, the patients studied had very severe AHF providing

  20. Slide 20: Cardiogenic Shock Development Strategy

    Cardiogenic Shock Development Strategy ‘SEISMIC Extension Study Extended and titrated dosing for optimization SEISMIC J Sst Ee on baa Study wath these tues augmented by AHF + Poot ot Concert > safety database. * SCAI Stage B due to AHF = Target Phase 3 start in * Learnings about dosing 2023 andeffec

  21. Slide 21: Plan for Dose Optimization — Extension Study

    Plan for Dose Optimization — Extension Study Following the positive results in the early cardiogenic shock study, an extension study is planned to support ‘ongoing development in early cardiogenic shock and acute heart failure Study objectives: v Advance the characterization of the physiology associ

  22. Slide 22: Istaroxime Acute Heart Failure

    Istaroxime Dual Mechanism SERCA2a Activator Acute Heart Failure o WINDTREE

  23. Slide 23: Heart Failure — Large, Growing Market But Underserved

    Heart Failure — Large, Growing Market But Underserved The prevalence and mortality of heart failure is high and increasing Annual Admissions Patients #1 cause of U.S. hospitalization ~1.3M us. 7us. in patients ~1.5M cv 25M + wordwide > 65 years old >$18B (') In-patient mortality annual U.S. hospital

  24. Slide 24: Acute Heart Failure — Significant Unmet Clinical Need

    Acute Heart Failure — Significant Unmet Clinical Need tient Management Goals * Clinical objectives for AHF patient management include: ~ Relieve pulmonary congestion and general edema (e.g., ‘dry out”) with IV diuretics ~ Improve cardiac function and peripheral/organ perfusion ~ Achieve stable, full

  25. Slide 25: Istaroxime AHF Phase 2a & 2b Studies

    Istaroxime AHF Phase 2a & 2b Studies Phase 2a Phase 2b Py WINDTREE SZ & © n=120 Dosing= 6 hour ADHE Patients 0.5, 1, 1.5 uokomn Infusion 24 hour Infusion n=120 Dosing ADHE Patients 0.5, 1.0 pokomin (ayseneapius need tor Rrosemae > mg) Po: Primary: PCWP significantly improved Stroke Vol & SBP ~ signi

  26. Slide 26: Primary Endpoint Achieved

    Primary Endpoint Achieved Significant Changes in E/e' Ratio’ and Stroke Volume Istaroxime 0.5 ug/kg/min vs. placebo Istaroxime 1.0 yg/kg/min vs. placebo

  27. Slide 27: Systolic Blood Pressure Increased During Treatment

    Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve Istaroxime 0.5 yg/kg/min vs. placebo 3° Systolic i* Blood a: Pressure H (SBP) $. 8, Istaroxime 1.0 yg/kg/min vs. placebo hange $80fmio)

  28. Slide 28: Heart Rate Decreased and No Increases in Cardiac Troponins

    Heart Rate Decreased and No Increases in Cardiac Troponins Istaroxime 0.5 yg/kg/min vs. placebo Istaroxime 1.0 yg/kg/min vs. placebo ee ; ; caked : * 4 Heart z aS ro GE Gl Rate i a5 a5 2 al £31 m | 8 *pvalue= 0.014 winbteee

  29. Slide 29: Favorable Profile Observed with 24-hour Holter Monitoring

    Favorable Profile Observed with 24-hour Holter Monitoring Clinically Significant Arrhythmias. Ventricular Tachycardia we we ]

  30. Slide 30: Istaroxime — Acute Heart Failure

    Istaroxime — Acute Heart Failure Objective: Optimize therapy and employ study enrichment strategies to create strong Phase 3 and partnership position Execute an addi ase 2 and inform Phase 3 ally’ Enrich therapeutic impact by leveraging characteristics in target population whose needs match the uniq

  31. Slide 31: Next Generation, Oral SERCA2a Activators

    Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform The Company also has pre-clinical programs on product candidates including: Selective SERCAZa Dual Mechanism, (SERCAZa & Nat/K+) Activators Compounds, + Oral & i.v. therapies for chronic “Next generation istaroxime” as

  32. Slide 32: Summary

    Summary V Istaroxime has produced positive, differentiating data in three Phase 2 studies for two separate and complementary indications. These markets have significant unmet needs, and no known other late-stage programs in development to address the acute decompensated patient The data is consisten

  33. Slide 33: Financial Summary & Capitalization

    Financial Summary & Capitalization Cash & Equivalents of ~$15.5 million as of March 31, 2022 Common Equival as of May 5, 2022 Common Stock 29,406,172 Options (WAEP $7.81) 4,163,934 Restricted Stock Units 554,000 Warrants (WAEP $9.43) 16,628,802 Fully Diluted Equivalents 50,752,908 bd WINDTREE

  34. Slide 34: Strategy for Value Generation

    Strategy for Value Generation Communicate Our Milestones Transactions v Optimization Y ‘Secure focused BD Bring in new, well- tensect fe co ore suited development Pe opportunities and development transactions Progress hear failure platform to an attractive and valuable position for global Partnershi

  35. Slide 35: Slide 35

  36. Slide 36: Appendix

    Appendix

  37. Slide 37: Istaroxime Unique Opportunity With Attractive Risk / Return Profile

    Istaroxime Unique Opportunity With Attractive Risk / Return Profile @© Hianly consistent resuits across 3 @© Artractive profile as the only acute heart failure or shock drug that has controlled Phase 2 studies (and been shown to significantly improve cardiac function of a failing heart, 300 patients

  38. Slide 38: Istaroxime AHF Phase 2b Adverse Events

    Istaroxime AHF Phase 2b Adverse Events xime 0.5 mglKgiminIstaroxime 1.0 mgKgimin (oat) 0) Event {All adverse events, 31 (756%) 39(625%) ‘Adverse events leading to discontinuation E 410.0%) Serious adverse events 261%) 249%) (150%) Cardiac death z z 125%) Carciogenic shock E = 125% Cardiac fare 126%)

  39. Slide 39: SEISMIC: Serious Adverse Events and Adverse Drug Reactions

    SEISMIC: Serious Adverse Events and Adverse Drug Reactions ime PI Event i ean ‘ll adverseevents 27 (99%) 25 (81%) Seriousadverse events 8 (21%) 6 (19%) Cardiac arrest 16%) ° Cardiac fare 207%) 216%) Cardiac failure acute 0 409%) Cardiac ventricular thrombosis 0 10%) Cardiac artery stenosis ° 10%) Ve

  40. Slide 40: SEISMIC: Safety and Efficacy More Favorable with 1.0 vs 1.5

    SEISMIC: Safety and Efficacy Appeared More Favorable with the 1.0 vs 1.5 yg/kg/min and Placebo 1.0 ug/kg/min dosing was associated with: Istaroxime Istaroxime Placeb [SBRAUC o-z4nrs; LS-Means(SE)" _209.9(27.38)_282.7(35.78) 304.1 (44.11) Worsening HF through 9€-hours Nacevanes 40%) (0%) 5 (08%) Eee

  41. Slide 41: Acute Heart Failure

    Acute Heart Failure Significant Healthcare Issue with Significant Unmet Clinical Need * Patients with low blood pressure (SBP) and peripheral hypoperfusion are high risk, challenging patients. These patients are also generally resistant to diuretic therapy and often discharged in a sub-optimal state

  42. Slide 42: Istaroxime Phase 2a (HORIZON-HF) Study

    Istaroxime Phase 2a (HORIZON-HF) Study * Multicenter, double blind, placebo-controlled, doses 6-hour infusion of istaroxime 0.5, 1.0, 1.5 ug/kg/min, conducted inthe EU + Hospitalized with AHF, with criteria including LVEF s35% SBP.90-150 mmHg 120 (30/group) * Significant improvement in PCWP, SBP, he

Windtree Therapeutics — Investor Presentation (July 2022) on 6ix